All In Biotech

Drug Trial Radar · NCT06006559

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Feb 20, 2024

Primary completion

Jul 22, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.

Conditions

  • Dengue

Interventions

  • EYU688Drug

    EYU688 administered by oral route

  • PlaceboDrug

    Matching placebo administered orally as capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment startTime frame: From predose to 48 hours post treatment start

Locations

27 sites in 7 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Manaus, Amazonas, Brazil · Recruiting

  • Novartis Investigative Site

    Brasília, Federal District, Brazil · Recruiting

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Novartis Investigative Site

    São Caetano do Sul, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Sorocaba, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Bucaramanga, Santander Department, Colombia · Recruiting

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Novartis Investigative Site

    Belagavi, Karnataka, India · Recruiting

  • Novartis Investigative Site

    Mumbai, Maharashtra, India · Withdrawn

  • Novartis Investigative Site

    Pune, Maharashtra, India · Recruiting

  • Novartis Investigative Site

    Jaipur, Rajasthan, India · Recruiting

  • Novartis Investigative Site

    Chennai, Tamil Nadu, India · Recruiting

  • Novartis Investigative Site

    Kuala Selangor, Malaysia · Recruiting

  • Novartis Investigative Site

    Kuantan, Pahang, Malaysia · Recruiting

  • Novartis Investigative Site

    Ipoh, Perak, Malaysia · Recruiting

  • Novartis Investigative Site

    Seberang Jaya, Pulau Pinang, Malaysia · Recruiting

  • Novartis Investigative Site

    Miri, Sarawak, Malaysia · Recruiting

  • Novartis Investigative Site

    Oaxaca City, Mexico · Recruiting

  • Novartis Investigative Site

    Veracruz, Mexico · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Haiphong, Vietnam · Recruiting

  • Novartis Investigative Site

    Hanoi, Vietnam · Recruiting

  • Novartis Investigative Site

    Ho Chi Minh City, Vietnam · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.